Iveric Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019
- Company to Host a Zimura® R&D Symposium for Investors on
To participate in this conference call, dial 888-208-1711 (
Zimura R&D Symposium for Investors
The Company also announced that it will host a Zimura R&D Symposium for Investors on
The event will be accessible via webcast on the IVERIC bio website at www.ivericbio.com. For more information, please contact
About IVERIC bio
IVERIC bio is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. Vision is Our Mission. For more information on the Company please visit www.ivericbio.com.
Any statements in this press release about IVERIC bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent IVERIC bio’s views only as of the date of this press release. IVERIC bio anticipates that subsequent events and developments will cause its views to change. While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191104005863/en/
Kathy Galante, 212-845-8231
Vice President, Investor Relations and Corporate Communications
Alex Van Rees, 973-442-1555 ext. 111